1. Introduction {#sec1}
===============

The human hCLCA1 protein is a member of the *CLCA* (chloride-channel modulating, calcium-activated) gene family with a well-established role in inflammatory airway diseases such as asthma, cystic fibrosis, and chronic obstructive pulmonary disease \[[@bib1], [@bib2], [@bib3], [@bib4]\]. Although hCLCA1 was originally identified as the pore subunit of calcium activated chloride channels, later studies have shown that it is a chloride channel accessory protein \[[@bib5], [@bib6], [@bib7], [@bib8], [@bib9]\]. Studies have reported that hCLCA1 is induced in inflamed airway epithelial cells, and this induced expression often exceeds that of most other inflammatory mediators \[[@bib10],[@bib11]\]. We have previously identified the novel role of hCLCA1 as a signaling molecule \[[@bib12]\], suggesting a possible mechanism by which hCLCA1 expression contributes to inflammatory airway disease.

In our previous study, we have demonstrated hCLCA1 acts as a signaling molecule and modulates innate immune response in macrophages \[[@bib12]\]. A recent study also demonstrated that mCLCA1 (formerly mCLCA3), the murine ortholog of hCLCA1, modulates leukocyte recruitment via IL-17 and CXCL-1 in bacterial pneumonia \[[@bib13]\], which is in line with our newly identified function of hCLCA1 as an immune modulator. However, the mechanism regarding this modulation remains unclear. In addition to the previously mentioned hydrolase domain (HYD), hCLCA1 also contains both von Willebrand factor A (VWA) and Fibronectin type III (FN3) domains. Such domains have been shown to play a role in different aspects of the inflammatory response. The hydrolase domain of hCLCA1 is similar to the protease domain of matrix metalloproteases, which are known to play a role in activation of pro-inflammatory cytokines such as IL-8 \[[@bib14],[@bib15]\]. The VWA domain is a ligand binding motif first described in the hemostasis protein Von Willebrand Factor and has been known to contribute to the inflammatory response through leukocyte recruitment \[[@bib16], [@bib17], [@bib18]\]. Finally, the FN3 domain has been shown to increase inflammatory cytokine expression in fibroblast cells \[[@bib19],[@bib20]\]. In this study, we expressed proteins containing different hCLCA1 domains to determine the specific domain(s) and associated pathways that are involved in hCLCA1 macrophage activation. The results demonstrate that the von Willebrand factor type A (VWA) domain of hCLCA1 can induce a modest up-regulatation of both mRNA and protein expression of IL-1β. Additionally, both the NF-κB and MAPK signaling pathways were activated when macrophages were exposed to VWA domain.

2. Materials and methods {#sec2}
========================

2.1. Cell culture {#sec2.1}
-----------------

Human monocytes (U-937 cell line; CRL1593.2; ATCC) were grown in RPMI-1640 medium supplemented with 10% heat inactivated Fetal bovine serum and 1% penicillin-streptomycin 37 °C in a humidified atmosphere with 5% CO~2~.

2.2. Cloning, expression, purification, and endotoxin removal of hCLCA1 domain containing proteins {#sec2.2}
--------------------------------------------------------------------------------------------------

DNA corresponding to the hydrolase domain (amino acids 1--273), von Willebrand Factor Type A (VWA) domain (amino acids 240--544), Hydrolase-VWA domain (amino acids 1--544), and Fibronectin type III (FN3) domain (amino acids 643--915) were amplified by PCR utilizing primers containing ligation-independent cloning tags ([Table 1](#tbl1){ref-type="table"}). PCR products were then cloned into a modified pET28 vector encoding a hexahistidine tag (His-tag) and maltose binding protein tag on the N-terminus using ligation independent cloning method \[[@bib21]\]. Success of cloning was confirmed by PCR and sequencing ([Table 2](#tbl2){ref-type="table"}).Table 1Primers used for cloning.Table 1Human CLCA1 PCR Primers for cloningPrimer NamePrimer Sequence (5′ → 3′)F.P. LIC-N1-hCLCA1TAC TTC CAA TCC AAT GCA ATG GGC CCC TTC AAGF.P. LIC-N240-hCLCA1TAC TTC CAA TCC AAT GCA GCC CAG CAC GTG GACF.P. LIC-N643-hCLCA1TAC TTC CAA TCC AAT GCA CTG GAC AAT GGA GCCR.P. LIC-C544-hCLCA1TTA TCC ACT TCC AAT GGC CTA CTT ATC GAC CAC AAAR.P. LIC-C915-hCLCA1TTA TCC ACT TCC AAT GGC TCA GGC GAT ACT CAGTable 2Primers used for sequencing.Table 2Human CLCA1 PCR Primers for sequencingPrimer NamePrimer Sequence (5′ → 3′)F.P. 306-hCLCA1ATA TAA AAA TGC AGA CGT GCT GGT CGC CGA AAR.P. 475-hCLCA1GCA GAG TAT GGG CCC CAG GGC CGA GCT TTT GF.P. 900-hCLCA1CTT CAG CCT GCT GCA GAT CGG GCA GCG GAT CF.P. 1522-hCLCA1GGC ACA GTG ATC GTC GAC TCA ACT GTG GGAF.P. 2215-hCLCA1GGG TCC TTT GTG GCT TCT GAC GTG CCA AAC GC

For protein expression *E. coli* Rosetta (DE3) cells carrying the plasmid of interest were grown in 2 YT broth containing antibiotic at 37 °C to an OD~600~ of ∼0.6 and induced with 0.2 mM IPTG, after which point the cultures were grown for 18--22 h at 18 °C. The cells were then harvested by centrifugation, resuspended in buffer A (250 mM KCl, 10 mM HEPES, 25 μg/mL DNase I, 25 μg/mL lysozyme, 1 mM PMSF and 10 mM βME, pH 7.4) and lysed by sonication. The soluble fraction was loaded onto a Ni^2+^-NTA (Bio-Rad Profinity IMAC resin. 1560123; Biorad) affinity column and eluted with a gradient of 20--300 mM imidazole. Eluted fractions were pooled and loaded onto an amylose (E8021S; New England Biolabs) column, with pure protein being eluted with 10 mM maltose. The eluted proteins were dialyzed against Buffer D (10 mM KCl and 20 mM HEPES pH 7.4) at 4 °C overnight and loaded onto a Resource Q anion exchange column (17117901; General Electric). Bound proteins were eluted with a gradient of 10--1000 mM KCl. The eluted proteins were then concentrated with Amicon ultra-15 centrifugal filter units (30 kDa MWCO, UFC903008; Fisher Scientific)and polished by gel-filtration chromatography on a Hiload 16/60 Superdex 200 column (28989335; General Electric) by running 1 column volume of Buffer A through the column. Eluted proteins were routinely assessed to be ≥ 95% pure utilizing SDS-PAGE and Coomassie staining. Eluted proteins were then concentrated to a final volume of ∼1.5 mL and treated with 1% triton-X114 for 20 min at 4 °C, 10 min at 37 °C, and centrifuged for 10 min at 20,000*g*. This process was repeated 3× to completely remove endotoxin residuals. Endotoxin contamination was assessed to be ≤ 0.01 EU/mL using a quantitative Limulus Amebocyte Lysate assay (L00350; Genscript). Protein concentration was estimated using the BCA assay (23225; Thermofisher).

2.3. Circular dichroism spectroscopy {#sec2.3}
------------------------------------

Proteins (500 μg/mL) were dialyzed into 25 mM sodium phosphate buffer (pH 7.4) containing 250 mM NaF and CD spectra were collected at 20 °C utilizing a PiStar-180 circular dichroism spectrometer with a 0.05 cm path-length cuvette. Four spectra from 260 to 190 nm were recorded with 0.5 nm resolution for each protein, averaged, and buffer subtracted.

2.4. Monocyte differentiation and activation {#sec2.4}
--------------------------------------------

Monocyte cells were seeded in each well (1.3 × 10^6^ to 1.5 × 10^6^ cells/well) in a 6-well plate and differentiated into macrophages with 0.1 nM phorbol-12-myristate-13-acetate (PMA) in supplemented FBS-free RPMI-1640 medium for 18 h. The cells were washed 2 times with FBS-free RPMI-1640 medium and incubated in supplemented RPMI-1640 medium containing 6% FBS. For the IL-1β experiment, 1 μg/mL or 5 μg/mL of different purified hCLCA1 domain proteins were added to macrophages for 48 h. For the cell signaling experiment, 5 μg of His-MBP or His-MBP-**VWA** proteins were added to macrophages for 2, 4, 6, or 12 h.

2.5. RNA isolation and real-time quantitative PCR {#sec2.5}
-------------------------------------------------

RNA was extracted using TRIzol reagent (15596026; Thermofisher) according to manufacturers' protocols. The collected RNA was analyzed with a GoTaq 2-Step RT-qPCR system and Mx3005P real-time PCR machine cDNA of each sample was measured in duplicates in Mx3005P real-time qPCR machine, and the average *C*~T~ (cycle threshold) value was used to calculate the fold difference of each gene. Primers were designed for GAPDH, TNF-α, IL-12a, IL-8, IL-1β, IL-6 and IL-10 ([Table 3](#tbl3){ref-type="table"}).Table 3Primers used in RT-qPCR experiments.Table 3Human qPCR PrimersGene NameForward Primers (5′ → 3′)Reverse Primers (5′ → 3′)GAPDHCAAGGTCATCCATGACAACTTTGGGGCCATCCACAGTCTTCTGTNF-αTGCTGCACTTTGGAGTGATCGTGCTACAACATGGGCTACAGGIL-12aCAGTGGAGGCCTGTTTACCATTGTACTACTAAGGCACAGGGCCATCIL-8TCTCTTGGCAGCCTTCCTGATTTCATTTCTGTGTTGGCGCAGTGTGIL-1βGCTGATGGCCCTAAACAGATGTGTAGTGGTGGTCGGAGATTCIL-6AGCCACTCACCTCTTCAGAACGTGCCTCTTTGCTGCTTTCACIL-10AAGCTGAGAACCAAGACCCAGACAAAAGGCATTCTTCACCTGCTCCAC

2.6. Efficiency and fold difference calculations {#sec2.6}
------------------------------------------------

Dilution series from 1 × 10^0^-fold to 1 × 10^−5^-fold of cDNA were used to determine the primer efficiency. The *C*~T~ value obtained in each dilution was used to generate a linear plot of *C*~T~ vs. log copies. The efficiency of the primer set was determined with the equation *Eff* = 10^(−1/slope)^. Primer efficiencies were within the range 1.9--2. The fold difference between hCLCA1\'s domains-activated and unstimulated samples was determined using an efficiency-corrected calculation with unstimulated macrophage served as control and GAPDH was served as reference gene \[[@bib22]\]:$$ratio = {\left( {Eff_{\text{target}}} \right)^{\Delta C_{T,\text{target}}{(\text{Mean}\ \text{control} - \text{Mean}\ \text{sample})}}/\left( {Eff_{\text{ref}}} \right)}^{\Delta C_{T,\text{ref}}{(\text{Mean}\ \text{control} - \text{Mean}\ \text{sample})}}$$

2.7. SDS-PAGE and western blot analysis {#sec2.7}
---------------------------------------

For IL-1β experiment, cell lysates were collected using M-PER mammalian protein extraction reagent (78501; Thermofisher) with the addition of Halt protease and phosphatase inhibitor cocktail (78440; Thermofisher). The cell lysates were resolved by SDS-PAGE and electroblotted onto a PVDF membrane. The membranes were probed overnight at 4 °C with primary antibodies GAPDH (1:1000) or IL-1β (1:500), then incubated for 1 h at room temperature with secondary antibodies (DyLight 488 conjugate Goat anti-Rabbit IgG antibody (35552; Thermo Scientific) and ECL Plex Goat anti-Mouse IgG-Cy5 antibody (PA45009; Amersham Biosciences). Proteins were detected and analyzed using Typhoon Trio and ImageQuant TL system.

For cell signaling experiment, stimulated macrophages were extracted using Pierce NE-PER nuclear and cytoplasmic extraction kit (78833; Pierce) with the addition of Halt protease and phosphatase inhibitor cocktail. The nuclear fractions were then resolved by SDS-PAGE and electroblotted onto PVDF membrane. After protein detection, the antibodies were removed from membrane by incubating with Amresco gentle review stripping buffer (N552; Amresco) for 30 min at room temperature, and the membranes were probed against primary β-actin antibody (C-4; sc-47778; Santa Cruz) overnight at 4 °C. The membranes were then incubated with secondary antibodies for 1 h at room temperature. Proteins were detected and analyzed using Typhoon Trio and ImageQuant TL system. Densitometry analysis of phosphorylated proteins was normalized to β-actin in each sample. Background noise is automatically calculated by ImageQuant analysis software, based on the most common pixel values around the target bands ('rolling ball' algorithm). The primary antibodies used were phospho-p44/42 MAPK (Thr202/Tyr204)), phospho-p38 MAPK (Thr180/Tyr182), phospho-SAPK/JNK (Thr183/Tyr185), and phospho-IKappaB-alpha (Ser32). The secondary antibodies used were DyLight 488 conjugate Goat anti-Rabbit IgG antibody and ECL Plex Goat anti-Mouse IgG-Cy5 antibody.

2.8. Statistics {#sec2.8}
---------------

All data are expressed as means ± standard error of the mean (SEM). The normality and variance tests were done using Shaprio-Wilk test and Levene\'s test respectively, and the fold difference values of RT-qPCR and IL-1β western blot densitometry were analyzed using ANOVA following Tukey\'s Honestly-Significant-Difference Test \[[@bib23]\]. For IL-1β expression western blot densitometry, the fold difference of hCLCA1 protein domain treated macrophages was compared to the media only negative control macrophages. For cell signaling western blot densitometry, the fold difference of His-MBP-VWA treated macrophages at given time points was compared to that of His-MBP treated macrophages at the same time points utilizing the Mann-Whitney U test. Each western blot was a result of an individual biological replicate. Significance was determined at *p \< *0.05.

3. Results and discussion {#sec3}
=========================

3.1. Purification of hCLCA1 domain proteins {#sec3.1}
-------------------------------------------

hCLCA1 cDNAs corresponding to the hydrolase domain (HYD) (amino acids 1--273), von Willebrand factor type A (VWA) domain (amino acids 240--544), and fibronectin type III (FN3) domain (amino acids 643--915) were ligated into a pET-28 expression vector containing an N-terminal hexahistidine-tag and maltose binding protein ([Fig. 1](#fig1){ref-type="fig"}-A). This created the His-MBP-**HYD**, His-MBP-**VWA**, and His-MBP-**FN3** constructs. These constructs were designed to comprise both the aforementioned protein domains and the flanking regions of each domain when possible. This was done in order to ensure proper folding of the functional hCLCA1 domains and to limit the size of the fusion proteins to ∼72 kDa. An additional construct comprising all 915 amino acids of hCLCA1 was also prepared, however the large size of this fusion protein negatively affected protein stability and this protein was unable to be successfully purified (data not shown). These constructs were initially purified by Ni^2+^ and amylose affinity chromatography, after which point anion exchange and size exclusion chromatography were utilized to remove contaminants from the final protein preparations. All proteins were determined to be \>95% pure by SDS-PAGE and Coomassie staining ([Fig. 1](#fig1){ref-type="fig"}-B). To verify folding of the maltose-binding protein-hCLCA1 domain fusion proteins far UV (260-190 nm) circular dichroism spectra of the three hCLCA1 constructs (His-MBP-**HYD**, His-MBP-**VWA**, and His-MBP-**FN3**) and the His-MBP protein were obtained ([Fig. 1](#fig1){ref-type="fig"}-C). Deconvolution of these spectra revealed all the protein constructs exhibited a mixture of α-helix and β-sheet secondary structure ([Table 4](#tbl4){ref-type="table"}). Of note was the dramatic increase in β-sheet secondary structure in His-MBP-**HYD** and His-MBP-**VWA**, with both constructs exhibiting ∼48% β-sheets (parallel and antiparallel combined), in contrast to the 21.3% β-sheet content calculated for His-MBP. While minima at 208 and 220 nm were apparent for the His-MBP-**FN3** spectrum ([Fig. 1](#fig1){ref-type="fig"}c), these did not translate into increased α-helical structure, as His-MBP-**FN3** possessed 30.1% β-sheet and only 14.7% α-helix. However, it is important to note that protein secondary structures calculated utilizing UV circular dichroism spectra are not definitive and may often differ greatly from data obtained by X-ray diffraction. This discrepancy is illustrated in the deconvolution of His-MBP protein, with the CDNN algorithm estimating 26.2% α-helix and 21.3% β-sheet (antiparallel and parallel combined) versus 43% α-helix and 20% β-sheet determined by X-ray diffraction \[[@bib24]\]. Nevertheless, the CD spectra of the His-MBP-hCLCA1 constructs differing from the His-MBP control, with regards to an increase in beta sheet content, indicates that our protein constructs are folded. While the protein preparations were relatively pure after Ni^2+^ and amylose affinity chromatography, anion exchange and size exclusion chromatography steps were required to remove small amounts of contaminants from the final preparations. Comparison of the size exclusion chromatography elution profiles of the hCLCA1 protein constructs ([Fig. 1](#fig1){ref-type="fig"}s) to a set of gel filtration standards indicated that the final purified proteins eluted at volumes consistent with monomeric (His-MBP-**HYD** and His-MBP-**FN3**) or dimeric (His-MBP-**VWA**) proteins.Fig. 1**hCLCA1 domain construct design, purification, and circular dichroism spectroscopy**: hCLCA1 is comprised of three functional domains (A, top): hydrolase (HYD), VWA, and FN3. Four constructs correlating to these domains were designed: amino acids **1--273** containing the hydrolase domain (His-MBP-**HYD**), amino acids **240--544** containing the VWA domain **(**His-MBP-**WVA)**, and amino acids **643--915** containing the FN3 domain (His-MBP-**FN3**). His-MBP-hCLCA1 domain fusion proteins were obtained from the soluble fraction by affinity, ion exchange, and size exclusion chromatography and were assessed by SDS-PAGE (B). Structural integrity of purified His-MBP and His-MBP-hCLCA1 fusion proteins was assessed by circular dichroism spectroscopy in the far UV region from 260 to 190 nm (C).Fig. 1Table 4**Estimated Secondary Structure of Protein Constructs Used in this study.** The CD spectra from [Fig. 1](#fig1){ref-type="fig"}-C were deconvoluted with CDNN software utilizing the "complex" sample dataset \[[@bib54]\].Table 4His-MBPHis-MBP-HYDHis-MBP-VWAHis-MBP-FN3α-Helix26.20%18.00%24.80%14.70%Antiparallel β-sheet13.40%40.00%37.90%24.60%Parallel β-sheet8.30%7.00%11.00%4.50%β-Turn14.80%16.10%11.80%23.60%Random Coil29.10%25.60%20.10%35.20%

*Escherichia coli* based expression systems are widely used for heterologous expression and purification of proteins, including immune modulators such as interferon-α \[[@bib25]\]. The maltose binding protein tag has found widespread use in *E. coli* based expression systems in recent years due to its ability to assist protein folding and improve solubility \[[@bib26],[@bib27]\]. While the use of the MBP tag in our expression system allowed us to express and purify large amounts of the above-mentioned protein constructs, removal of the His-MBP tags by TEV protease cleavage resulted in a dramatic loss of protein stability. As a result, the His-MBP affinity tags were not cleaved off our protein constructs in subsequent experiments.

3.2. Activation of U-937 macrophages with hCLCA1 domains {#sec3.2}
--------------------------------------------------------

Macrophage activation by hCLCA1 was investigated using the U-937 macrophage cell line treated with 1 or 5 μg/mL of purified hCLCA1 domain proteins for 48 h; macrophage activation was assessed by expression of the pro-inflammatory cytokines TNF-α, IL-8, IL-1β, IL-6, and IL-10. Treatment with 1 μg/mL hCLCA1 constructs did not elicit an inflammatory response (data not shown), while treatment with 5 μg/mL His-MBP-**VWA** induced modest induction of IL-1β mRNA, with a 2.08 ± 0.19 fold increase over control observed ([Fig. 2](#fig2){ref-type="fig"}). The increase in IL-1β mRNA expression was translated into an elevated IL-1β protein expression, with western blot analysis again showing a modeset 2.38 ± 0.18 fold increase in IL-1β protein expression in His-MBP-**VWA** treated macrophages over the control ([Fig. 3](#fig3){ref-type="fig"}). In our previous study IL-1β was the most induced cytokine activated by immune-purified hCLCA1 \[[@bib12]\], and was used as a marker of macrophage activation in the current work. Conversely, TNF-α, IL-8, IL-6, and IL-10 mRNA levels were not increased to a statistically significant level upon treatment with any of the hCLCA1 protein constructs, although His-MBP-**VWA** was capable of upregulating IL-6 transcripts 1.63 ± 0.18 fold over the media control.Fig. 2**Effect on cytokine expression of macrophages exposed to 5 μg/mL purified hCLCA1 domains.** U-937 macrophages were treated for 48 h using 5 μg/mL of different purified hCLCA1 domain proteins. TNF-α, IL-8, IL-1β, IL-6, and IL-10 mRNA expression was quantified using RT-qPCR. The fold difference of each sample was compared against the control. Results were the means of 5 samples ± SEM. Significant fold differences from corresponding control values are indicated by \* (*p* \< 0.05).Fig. 2Fig. 3**VWA containing domain (amino acids 240--544) of hCLCA1 increased IL-1β protein expression level.** U-937 macrophages were treated for 48 h using 5 μg/mL of different purified hCLCA1 domain proteins. IL-1β protein levels were then assessed by western blotting. The fold difference of each sample was compared against the negative control (media only). Results were the means of 3 samples ± SEM. Significant fold differences from corresponding control values are indicated by \* (*p* \< 0.05).Fig. 3

In our previous study, ∼150 pg/mL of immuno-purified hCCLA1 was sufficient to induce macrophage activation \[[@bib12]\], while another study reported a physiological hCLCA1 concentration of ∼0.23 μg/mL in IL-13 induced NHBE cells \[[@bib28]\], values that are several orders of magnitude lower than the 5 μg/mL doses used in this experiment. One possible explanation for this discrepancy is the inability of our *E. coli* based expression system to post-translationally glycosylate expressed proteins \[[@bib29]\]. Secreted hCLCA1 has been shown to be a highly glycosylated protein \[[@bib30],[@bib31]\], and glycosylation is known to modulate the structure and function of signaling molecules \[[@bib32], [@bib33], [@bib34]\]. Additionally, while prior studies have reported that the MBP tag does not affect bioactivity of purified proteins \[[@bib35],[@bib36]\], we cannot preclude the possibility that the MBP tag may impair macrophage activation by His-MBP-**VWA** due to conformational hindrance. Finally, a 3 step Triton X-114 phase separation protocol was required to reduce endotoxin levels of purified hCLCA1 constructs below 0.01 EU/mL. Given that Adam et al., reported a 50% loss of bioactivity utilizing a 2-step Triton X-114 endotoxin removal protocol \[[@bib37]\] it is possible that the high dose of His-MBP-**VWA** required for macrophage activation in this experiment was a result of reduced protein activity.

The VWA domain was first identified in von Willebrand factor, a protein responsible for platelet and collagen binding during hemostasis \[[@bib38]\]. Since this initial discovery VWA domains have been identified in a variety of proteins such as integrins, extracellular matrix proteins, collagens, where they primarily function as adhesion molecules \[[@bib39], [@bib40], [@bib41], [@bib42]\]. This adhesion functionality plays a crucial role in the inflammatory response, as von Willebrand factor has been shown to facilitate leukocyte and neutrophil recruitment and adhesion during inflammation \[[@bib16], [@bib17], [@bib18]\]. In some cases, this adhesion to von Willebrand factor by leukocytes was shown to be mediated by β~2~ integrins \[[@bib17]\]. Interestingly, several other VWA domain containing proteins are known to adhere to integrins. In particular, matrilins 1, 2, and 3 interact with integrin α~1~β~1~ \[[@bib43],[@bib44]\], while the basement membrane protein AMACO promotes cell attachment to β~1~ integrins \[[@bib45]\]. β~1~ and α~V~β~3~ integrins have been shown to induce activation of both NF-κB and MAPK pathways in response to ligand binding \[[@bib46],[@bib47]\]. This activation resulted in increased expression of the pro-inflammatory cytokines TNF-α, IL-1β, IL-6, and IL-8 in macrophages \[[@bib47]\]. Thus macrophage activation induced by the VWA domain of hCLCA1 could be due to integrin binding and subsequent downstream signaling effects.

3.3. Phosphorylation of MAPKs and NF-κB pathways by VWA domain {#sec3.3}
--------------------------------------------------------------

Given the precedence for VWA domain induced integrin binding, as well as the role of the MAPK and NF-κB pathways induced by integrin activation in IL-1β expression \[[@bib48], [@bib49], [@bib50], [@bib51], [@bib52], [@bib53]\], we sought to investigate potential activation of the MAPK and NF-κB pathways by the hCLCA1 VWA domain. For this experiment macrophages were induced with 5 μg/mL His-MBP-**VWA** for 2, 4, 6, or 12 h and activation of the MAPK pathway was then assessed by quantification of phosphorylated p38, ERK, and JNK by western blotting, while quantification of phosphorylated IκB-α was used to examine activation of the NF-κB pathway.

Western blot and densitometry analysis showed that His-MBP-**VWA** significantly increased levels of phosphorylated IκB-α ([Fig. 4](#fig4){ref-type="fig"}A), p38 ([Fig. 4](#fig4){ref-type="fig"}B), and ERK ([Fig. 4](#fig4){ref-type="fig"}C) in macrophages over the His-MBP activated macrophages. While IκB-α phosphorylation was only significantly greater than control at 12 h, large (4.58 and 4.95 fold) increases in phosphorylation were apparent at 2 and 4 h, while the level of phosphorylation plateaued after 6 h, suggesting an early activation of the NF-κB pathway. Conversely, increased levels of phosphorylation of p38 and ERK were only apparent after 4 h of incubation and appeared to increase in a linear fashion until the end of the 12 h timepoint. Macrophage treatment with His-MBP**-VWA** did not induce detectable levels of phosphorylated JNK, while p-JNK was detected in LPS stimulated macrophages ([Fig. s2](#appsec1){ref-type="sec"}), suggesting that the signaling response observed was solely due to macrophage activation by the hCLCA1 VWA domain and not due to residual endotoxin contamination.Fig. 4**Levels of phosphorylated IκB-α, p38 and ERK with VWA domain treatment.** U-937 macrophages were treated for 2, 4, 6, or 12 h with 5 μg/mL of His-MBP or His-MBP-VWA protein. The levels of phosphorylated IκB-α (A), p38 (B) and ERK (C) was then assessed by western blotting. The fold difference of each sample was compared against His-MBP treated macrophage at 1 h. Results were the means of 3 samples ± SEM. Significant fold differences from corresponding control values at the given timepoints are indicated by \* (*p* \< 0.05).Fig. 4

In the present study we have identified the VWA domain of hCLCA1 to be sufficient for macrophage activation, inducing modest expression of IL-1β in U-937 macrophages. This activation was shown to correlate with the activation of NF-κB and MAPK pathways, both of which have been implicated in inflammatory cytokine expression. The activation of macrophages by hCLCA1 would modify the inflammatory response, mucus secretion, and airway higher responsiveness. Thus, identification of the protein domain within hCLCA1 with signaling function is of great therapeutic interest, as it provides a specific target to one of the most highly induced gene products of airway inflammatory disease.

Appendix A. Supplementary data {#appsec1}
==============================

The following are the Supplementary data to this article:Multimedia component 1**Representative size exclusion elution profiles of molecular size standards, His-MBP**-**HYD, His-MBP-VWA, and His-MBP-FN3**. The elution profile of the Hiload 16/60 Superdex 200 column was first established with a set of gel filtration standards (1511901; Biorad) of sizes 670 kDa (thyroglobin, A), 150 kDa (immunoglobulin gamma, B), 44 kDa (ovalbumin, C), 17 kDa (myoglobin, D), and 1.35 kDa (vitamin B12, E). Representative chromatograms of the purification of His-MBP**-HYD,** His-MBP-**VWA**, and His-MBP-**FN3** are attached. High molecular weight aggregates (\>600 kDa), dimeric protein (∼150 kDa calculated MW), monomeric protein (∼72 kDa calculated MW), and small impurities (≤45 kDa calculated MW) are annotated on each chromatogram. In all cases monomeric His-MBP-hCLCA1 domain proteins were isolated and used for downstream applications, with the exception of His-MBP-**VWA**, which could only be isolated as a dimer.Multimedia component 1Multimedia component 2**Validation of phospho-specific antibodies with LPS-induced macrophages.** Macrophages were activated with 1 μg/mL LPS for 4 h before protein isolation. Nuclear fraction proteins were analyzed with western blot against different phosphor-specific antibodies: p-IκB-α, p-p38, p-ERK, and p-JNK. A representative blot showing no detectable p-JNK from macrophages stimulated with His-MBP-VWA for 12 h is also shown.Multimedia component 2
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